Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies - PubMed (original) (raw)
Comparative Study
. 1983 Jul;43(7):3327-34.
- PMID: 6303581
Comparative Study
Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies
C J Wikstrand et al. Cancer Res. 1983 Jul.
Abstract
We have investigated the antigenic heterogeneity of human glioma cells and its correlation with other parameters of tumor cell heterogeneity (karyotype, 2':3' cyclic nucleotide 3'-phosphohydrolase expression, in vitro morphology) using the established human glioma cell line D-54 MG and eight single-cell-derived clones. The panel of antibodies used included 3 previously described heterologous sera raised against human gliomas and lamb oligodendroglia and 10 monoclonal antibodies with demonstrated reactivity for tumors of neuroectodermal origin, human fetal tissue, or human Thy-1. Antigen expression was determined by cell surface radioimmunoassay and peroxidase-antiperoxidase immunohistology. The use of a monoclonal antibody panel composed of ten reagents of varied specificity resulted in the demonstration of highly variable and complex antigenic patterns on the cell surfaces of cloned subpopulations of the human glioma cell line D-54 MG. Only one antigen, human Thy-1, was present on the parent line and all clones; the remaining nine antigens exhibited a distribution unrelated to other predictive parameters of genotypic or phenotypic heterogeneity such as karyotype, 2':3' cyclic nucleotide 3'-phosphohydrolase expression, or in vitro morphology. With the exception of clones 3 and 4, which shared a common antigen profile but exhibited distinctly different in vitro morphological patterns, the detected antigenic profile of each clone was distinct, with the proportion of expressed antigens ranging from 2 of 10 (clone 2) to 10 of 10 (clone 1). The demonstration of distinct, selectively maintained cell subpopulations within a human glioma cell line has direct implications for immunotherapeutic designs.
Similar articles
- Antigenic heterogeneity of human brain tumors defined by monoclonal antibodies.
Stavrou D, Bise K, Groeneveld J, Stocker U, Kretzschmar HA, Keiditsch E, Mehraein P. Stavrou D, et al. Anticancer Res. 1989 Nov-Dec;9(6):1489-96. Anticancer Res. 1989. PMID: 2697177 - Production and characterization of two human glioma xenograft-localizing monoclonal antibodies.
Wikstrand CJ, McLendon RE, Bullard DE, Fredman P, Svennerholm L, Bigner DD. Wikstrand CJ, et al. Cancer Res. 1986 Nov;46(11):5933-40. Cancer Res. 1986. PMID: 3756930 - Human glioma-associated antigens detected by monoclonal antibodies.
Schnegg JF, Diserens AC, Carrel S, Accolla RS, de Tribolet N. Schnegg JF, et al. Cancer Res. 1981 Mar;41(3):1209-13. Cancer Res. 1981. PMID: 7459861 - Patterns of antigenic expression of human glioma cells.
McKeever PE, Davenport RD, Shakui P. McKeever PE, et al. Crit Rev Neurobiol. 1991;6(2):119-47. Crit Rev Neurobiol. 1991. PMID: 1934088 Review. - Modulation of human tumor antigen expression.
Greiner JW, Hand PH, Colcher D, Weeks M, Thor A, Noguchi P, Pestka S, Schlom J. Greiner JW, et al. J Lab Clin Med. 1987 Mar;109(3):244-61. J Lab Clin Med. 1987. PMID: 2434589 Review.
Cited by
- Immunobiology of brain tumors.
Frank E, de Tribolet N. Frank E, et al. Neurosurg Rev. 1986;9(1-2):31-7. doi: 10.1007/BF01743051. Neurosurg Rev. 1986. PMID: 3090477 - The immunobiology of human gliomas.
Piguet V, Diserens AC, Carrel S, Mach JP, de Tribolet N. Piguet V, et al. Springer Semin Immunopathol. 1985;8(1-2):111-27. doi: 10.1007/BF00197250. Springer Semin Immunopathol. 1985. PMID: 3890235 Review. No abstract available. - Immunology of gliomas.
de Tribolet N. de Tribolet N. Childs Nerv Syst. 1989 Apr;5(2):60-5. doi: 10.1007/BF00571111. Childs Nerv Syst. 1989. PMID: 2660987 Review. - Glioblastoma multiforme: a look inside its heterogeneous nature.
Inda MM, Bonavia R, Seoane J. Inda MM, et al. Cancers (Basel). 2014 Jan 27;6(1):226-39. doi: 10.3390/cancers6010226. Cancers (Basel). 2014. PMID: 24473088 Free PMC article. - Mutated IDH1 is a favorable prognostic factor for type 2 gliomatosis cerebri.
Kwon MJ, Kim ST, Kwon MJ, Kong DS, Lee D, Park S, Kang SY, Song JY, Nam DH, Kato Y, Choi YL, Suh YL. Kwon MJ, et al. Brain Pathol. 2012 May;22(3):307-17. doi: 10.1111/j.1750-3639.2011.00532.x. Epub 2011 Nov 14. Brain Pathol. 2012. PMID: 21929658 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous